Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?

Opportunistic Infections Project Team of the, Collaboration of ObCollaboration of ObOpportunistic Infections Project Team of theMocroft, AmandaAmandaMocroftReiss, PeterPeterReissKirk, OleOleKirkMussini, CristinaCristinaMussiniGirardi, EnricoEnricoGirardiMorlat, PhilippePhilippeMorlatStephan, ChristophChristophStephanDe Wit, StephaneStephaneDe WitDoerholt, KatjaKatjaDoerholtGhosn, JadeJadeGhosnBucher, Heiner CHeiner CBucherLundgren, Jens DJens DLundgrenChene, GenevieveGenevieveCheneMiro, Jose MJose MMiroFurrer, HansjakobHansjakobFurrer0000-0002-1375-31462024-10-102024-10-102010https://boris-portal.unibe.ch/handle/20.500.12422/73393Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count >200 cells/microL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101-200 cells/microL.enIs it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?article10.48350/27022064586200028062390002110.1086/655761